Your browser doesn't support javascript.
The Impact of Serum Albumin Levels on COVID-19 Mortality.
Zerbato, Verena; Sanson, Gianfranco; De Luca, Marina; Di Bella, Stefano; di Masi, Alessandra; Caironi, Pietro; Marini, Bruna; Ippodrino, Rudy; Luzzati, Roberto.
  • Zerbato V; Infectious Diseases Unit, Trieste University Hospital (ASUGI), 34125 Trieste, Italy.
  • Sanson G; Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34149 Trieste, Italy.
  • De Luca M; Operative Unit of Medicina Clinica, Trieste University Hospital (ASUGI), 34125 Trieste, Italy.
  • Di Bella S; Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34149 Trieste, Italy.
  • di Masi A; Department of Sciences, Roma Tre University, 00146 Roma, Italy.
  • Caironi P; Department of Anaesthesia and Critical Care, AOU S. Luigi Gonzaga, Department of Oncology, University of Turin, 10043 Turin, Italy.
  • Marini B; Ulisse BioMed Labs, Area Science Park, SS 14, km 163.5, 34149 Trieste, Italy.
  • Ippodrino R; Ulisse BioMed Labs, Area Science Park, SS 14, km 163.5, 34149 Trieste, Italy.
  • Luzzati R; Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34149 Trieste, Italy.
Infect Dis Rep ; 14(3): 278-286, 2022 Apr 20.
Article in English | MEDLINE | ID: covidwho-2288431
ABSTRACT
Low serum albumin (SA) correlates with mortality in critically ill patients, including those with COVID-19. We aimed to identify SA thresholds to predict the risk of longer hospital stay, severe respiratory failure, and death in hospitalized adult patients with COVID-19 pneumonia. A prospective longitudinal study was conducted at the Infectious Diseases Unit of Trieste University Hospital (Italy) between March 2020 and June 2021. The evaluated outcomes were (1) need of invasive mechanical ventilation (IMV); (2) length of hospital stay (LOS); and (3) 90-day mortality rate. We enrolled 864 patients. Hypoalbuminemia (<3.5 g/dL) was detected in 586 patients (67.8%). SA on admission was significantly lower in patients who underwent IMV (2.9 vs. 3.4 g/dL; p < 0.001). The optimal SA cutoff predicting the need of IMV was 3.17 g/dL (AUC 0.688; 95% CI 0.618-0.759; p < 0.001) and this threshold appeared as an independent risk factor for the risk of IMV in multivariate Cox regression analysis. The median LOS was 12 days and a higher SA was predictive for a shorter LOS (p < 0.001). The overall 90-day mortality rate was 15%. SA was significantly lower in patients who died within 90 days from hospital admission (3.1 g/dL; IQR 2.8-3.4; p < 0.001) as compared to those who survived (3.4 g/dL; IQR 3.1-3.7). The optimal SA threshold predicting high risk of 90-day mortality was 3.23 g/dL (AUC 0.678; 95% CI 0.629-0.734; p < 0.001). In a multivariate Cox regression analysis, SA of <3.23 g/dL appeared to be an independent risk factor for 90-day mortality. Our results suggest that low SA on admission may identify patients with COVID-19 pneumonia at higher risk of severe respiratory failure, death, and longer LOS. Clinicians could consider 3.2 g/dL as a prognostic threshold for both IMV and mortality in hospitalized COVID-19 patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Journal: Infect Dis Rep Year: 2022 Document Type: Article Affiliation country: Idr14030034

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Journal: Infect Dis Rep Year: 2022 Document Type: Article Affiliation country: Idr14030034